Actos Diabetes Treatment Litigation
Actos (pioglitazone) is a best-selling drug used to treat Type 2 Diabetes. Actos has been on the market since July of 1999, and it is estimated that more than two million type II diabetes patients have taken the drug.
In September of 2010, the FDA received data that links the drug to an increased risk of bladder cancer, particularly in men.
Since 2010, Actos has remained under long-term observational study by the FDA, but remains on the shelves. In 2011, the FDA released a warning to the public regarding the cancer link.
Who Is At Risk For Bladder Cancer?
It was found that the longer a patient takes Actos, and the higher the dosage, the greater the risk for developing bladder cancer. In other words, the more Actos you take, the higher your risk.
A French study found that the cumulative dose of greater than 28,000 milligrams overtime led to a significant increase in bladder cancer, particularly in men.
Cancer Risk In Avandia?
Actos was originally marketed by Takeda Pharmaceuticals as a safe alternative to Avandia (rosiglitazone). Avandia was found to have several heart-related side effects. Since the link between Avandia and heart problems was announced, sales of Actos has grown substantially.
No studies have shown a bladder cancer risk in Avandia, however, Actos is often prescribed to patients who are already at risk for heart conditions.
Bladder Cancer Symptoms
If you or a loved one takes Actos to treat type two diabetes, it is important to know the signs and symptoms of bladder cancer. Call a doctor if you notice:
- Blood in urine
- Frequent urination
- Painful urination
- Urinary tract infection
- Discomfort in lower back
When To Call A Lawyer
If you have been diagnosed with bladder cancer after taking Actos, Schultz & Myers is here to help. Call us at 314.444.4444 for a free consultation. Consider how long you have been taking Actos, and at what dosage. This information can help an attorney gain an understanding of your situation.